系统性自身免疫性风湿病患者COVID-19结局的时间趋势:从第一波到初始奥密克戎波
在Mass General Brigham开展的回顾性队列研究,纳入2020年3月1日至2022年1月31日确诊COVID-19的系统性自身免疫性风湿病患者1449例,其中重症399例(28%)。重症比例随日历时间下降,早期COVID-19期为46%,初始奥密克戎波为15%(校正OR 0.29,95%CI 0.19至0.43)。
要点
- 重症COVID-19比例随日历时间下降,趋势检验P<0.001。
- 早期COVID-19期重症46%,初始奥密克戎波15%,校正OR 0.29(95%CI 0.19至0.43)。
- 未接种疫苗者中重症比例高于非重症者(78% vs 60%)。
核心结论
- 系统自身免疫性风湿病患者中重症COVID-19比例自疫情早期以来已下降,尤其在包括初始奥密克戎波在内的最近时间段。
- 作者认为COVID-19预防、诊断和治疗的进步可能改善了系统自身免疫性风湿病患者的结局。
研究设计与样本
- 回顾性队列研究,研究2020年3月1日至2022年1月31日在Mass General Brigham系统识别并确诊COVID-19的系统自身免疫性风湿病患者。
- 共识别1449例系统自身免疫性风湿病合并COVID-19患者,平均年龄58.4岁,女性75.2%,类风湿关节炎33.9%。
主要发现
- 1449例中重症COVID-19(住院或死亡)399例(28%)。
- 重症COVID-19比例随日历时间下降(趋势检验P<0.001)。
- 早期COVID-19期(2020年3月1日至2020年6月30日)重症占46%,初始奥密克戎波(2021年12月17日至2022年1月31日)为15%,校正OR 0.29(95%CI 0.19至0.43)。
- 未接种疫苗者在重症病例中占78%,在非重症病例中占60%。
关键数值与推荐
- 重症COVID-19定义为住院或死亡,共399例(28%)。
- 以早期COVID-19期为参照,初始奥密克戎波重症COVID-19的校正OR为0.29(95%CI 0.19至0.43)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate temporal trends in incidence and severity of COVID-19 among patients with systemic autoimmune rheumatic diseases (SARDs) from the first wave through the initial Omicron wave. METHODS: We conducted a retrospective cohort study investigating COVID-19 outcomes among patientswith SARD systematically identified to have confirmed COVID-19 from 1 March 2020 to 31 January 2022 at Mass General Brigham. We tabulated COVID-19 counts of total and severe cases (hospitalisations or deaths) and compared the proportion with severe COVID-19 by calendar period and by vaccination status. We used logistic regression to estimate the ORs for severe COVID-19 for each period compared with the early COVID-19 period (reference group). RESULTS: We identified 1449 patients with SARD with COVID-19 (mean age 58.4 years, 75.2% female, 33.9% rheumatoid arthritis). There were 399 (28%) cases of severe COVID-19. The proportion of severe COVID-19 outcomes declined over calendar time (p for trend <0.001); 46% of cases were severe in the early COVID-19 period (1 March 2020-30 June 2020) vs 15% in the initial Omicron wave (17 December 2021-31 January 2022; adjusted OR 0.29, 95% CI 0.19 to 0.43). A higher proportion of those unvaccinated were severe compared with not severe cases (78% vs 60%). CONCLUSIONS: The proportion of patients with SARD with severe COVID-19 has diminished since early in the pandemic, particularly during the most recent time periods, including the initial Omicron wave. Advances in prevention, diagnosis and treatment of COVID-19 may have improved outcomes among patients with SARD.
引用
- Kawano Y, Patel NJ, Wang X, et al. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. Ann Rheum Dis. 2022. PMID: 35944947. doi:10.1136/ard-2022-222954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。